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Abstract
Phosphatase of regenerating liver-1 (PRL-1) is a novel target for potentially treating cancer
metastases. Although its specific biochemical role in these processes has yet to be delineated,
considerable evidence suggests the phosphatase activity of PRL-1 is required for promoting cancer
and metastasis. PRL-1 belongs to the protein tyrosine phosphatase (PTPase) family and functions
using the CX5R consensus active site motif. Like other PTPases, PRL-1 is inhibited by oxidation at
its active site Cys, however, disulfide bond formation occurs unusually readily in wild-type PRL-1.
Chemical shift assignments are available for oxidized wild type, but numerous, substantial changes
are observed in the spectra upon reduction. Because the reduced form is active, we sought to identify
a stable mutant that would resist oxidation and be useful for facilitating drug screening and
development using NMR-based assays. We present here NMR assignments for a full-length, reduced
and active form of PRL-1, PRL-1-C170S-C171S, that is well suited for this purpose.
Biological Content
Phosphatase of regenerating liver (PRL) enzymes have become sought after targets for drug
design because they aggressively promote cancer and metastasis. Elevated levels of the
individual PRLs (PRL-1, PRL-2, and PRL-3) are found in many cancer tissues when compared
with their normal counterparts, and their overexpression has been shown to increase growth
rates and motility in cultured cells as well as cause tumorigenesis and metastasis in vivo.
Additionally, elevated levels of PRL-1 and PRL-3 may play a causal role in promoting tumor
cell motility and invasion (Stephens et al. 2005).
The PRL enzymes (20 kDa) belong to the protein tyrosine phosphatase family, which contain
the signature CX5R active site motif. Dephosphorylation of substrates is accomplished by a
two-step mechanism, which involves nucleophilic attack by the active site Cys on the
phosphorous atom followed by hydrolysis to release the phosphate moiety from the enzyme
(Sun et al. 2005). While the biochemical pathways by which each PRL enzyme functions
remain to be determined, studies have shown that the phosphatase activity of PRL-1 is required
for normal mitotic progression and that activity of these enzymes is redox regulated such that
direct oxidation of the nucleophilic Cys inhibits activity (Stephens et al. 2005). This indicates
the reduced form of the PRL-1 protein is the relevant target for development of anticancer
therapeutics. A previously published crystal structure of wild-type PRL-1 reveals a disulfide
bond forms between the active site Cys (C104) and nearby partner C49, inhibiting its activity
(Sun et al. 2005). A second crystal structure of the reduced but inactive PRL-1 mutant
(PRL-1C104S) reveals an altered organization of the active site residues that is conducive to
substrate binding (Jeong et al. 2005; Sun et al. 2005). In order to conduct biologically relevant
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in vitro drug screening assays, identification of a stable, reduced and active form of PRL-1 is
needed.
Previously, the 1H, 15N, and 13C resonance assignments were reported for PRL-1 under
nonreducing conditions (Laurence et al. 2004) and for PRL-2 and PRL-3 under reducing
conditions (Kozlov et al. 2002; Zhou et al. 2003). Comparison of these very closely related
homologues (>75% identity) reveals differences in conformation between the reduced and
oxidized forms. Consequently, the majority of chemical shift positions of resonances from
reduced PRL-1 are substantially altered compared to those of the previously reported oxidized
form. We present here the 1H, 15N and 13C resonance assignments of a full-length, reduced
and active form of PRL-1 that will facilitate NMR-based drug screening.
Methods and Experiments
NMR-based structure determination of the wild-type PRL-3 enzyme under reducing conditions
resulted in a disordered active site (Kozlov et al. 2004). Similarly, assignments for the active
site residues were not possible to obtain for PRL-1 under non-reducing conditions (Laurence
et al. 2004). The lack of data from the active site region in both cases may likely be due to
dynamics caused by chemical exchange of the reducing agent with the active site thiol and
disulfide bond. Because of this, mutagenesis studies were carried out to identify a fully active
and stable form of PRL-1 that is less susceptible to oxidation and amenable for use in drug
screening assays. The PRL-1-C170S-C171S protein meets these criteria and permitted
successful assignment of the active site resonances in the reduced form. Reduced forms of
PRL-1 have been identified previously by X-ray crystallography; however, in order to maintain
the reduced state, numerous changes to the primary sequence were required (Sun et al. 2005;
Jeong et al. 2005). The cysteine mutations are a more conservative change to the protein
sequence and permitted assignments of full-length PRL-1.
The PRL-1 gene was cloned into the pET-30 Xa LIC vector as described previously (Laurence
et al. 2004). The PRL-1 wild-type DNA was mutated to C170S-171S in two rounds using the
PCR-based QuikChange method (Stratagene). The primers used to generate the C170S and
C171S mutants were 5’-ggtcatagaaacaactCttgcattcaataaggatc-3’ and 5”-
ggtcatagaaacaactgttCcattcaataaggctgtaactc-3’ (Integrated DNA Technologies, Coralville, IA),
respectively. Capital letters indicate the mutated bases. PCR reactions were treated with DpnI
(Promega) for 1.5 hours at 37°C, directly transformed into NovaBlue GigaSingles Competent
cells (Novagen) and spread on LB agar plates containing 30 mg/mL kanamycin (Kan30) to
select for transformed cells. Individual colonies were cultured overnight in LB Kan30 at 37°
C. The resultant DNA was purified using the Wizard Plus MiniPrep System (Promega). The
double mutant C170S-C171S was produced by a second round of mutagenesis. The mutated
DNA was confirmed to have the correct sequence by bidirectional sequencing using the T7
promoter and T7 terminator primers (Northwoods DNA, Inc., Bemidjii, MN). The plasmid
was transformed into BL21 (DE3) competent cells and selected based on kanamycin resistance.
The PRL-1-C170S-C171S protein was expressed and purified using the same procedure as
described previously for the wild-type protein (Laurence et al. 2004). Purified proteins were
concentrated to approximately 1.5 mM protein in 50 mM sodium phosphate, pH 6.5 using
Amicon Ultra 10 kDa MWCO centrifugal filters to generate the NMR samples used to collect
resonance assignment data.
NMR samples contained 5% D2O and were analyzed in Shigemi tubes. 2D 1H-15N HSQCs,
3D versions of the CBCA(CO)NH, HNCACB, C(CO)NH and HNCO experiments were carried
out on a Bruker Avance 800 MHz NMR spectrometer using a cryogenic, triple-resonance probe
equipped with pulse field gradients. All spectra were obtained at 37°C and referenced relative
to DSS (Wishart et al. 1995). Spectra were processed using NMRpipe (Delaglio et al. 1995)
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and peak picked using Sparky (Goddard and Kneller). Peak lists were submitted to the PINE
Server through NMRFAM, University of Wisconsin, Madison (Eghbalnia et al. 2005). All
automated assignments were manually verified using Sparky.
Extensive studies were performed to identify the stably reduced from of PRL-1 that was used
to obtain resonance assignments of the active enzyme, and as such, the data will be presented
elsewhere (Skinner et al., in preparation). Briefly, each sample was analyzed by SDS-PAGE
to verify purity and subjected to trypsin digest followed by ESI-MS to determine the redox
state of the active site. A standard phosphatase activity assay with p-nitrophenyl phosphate
(pNPP) was used to determine the relative activity of the C170S-C171S mutant compared to
the wild-type PRL-1. Assay mixtures contained 50 mM HEPES, pH 7.5, 20 mM pNPP, and
0–10 mM DTT. Reactions were initiated by the addition of 1 mg/mL PRL-1 and monitored
for absorption at 405 nm. The MS data indicate no disulfide bond formation occurs at the active
site of C170S-C171S, and the activity data indicate that this mutant protein dephosphorylates
pNPP in the absence of reducing agents as well as the chemically reduced wild-type PRL-1
(unpublished data).
Assignments and Data Deposition
Greater than 90% of the NH, CO, Cα and Cβ resonances were assigned for PRL-1-C170S-
C171S. Complete sequential backbone assignments were achieved for residues V10-Q173 with
the exception of residues N27, E36, T52, E59, A111, R137 and R138 and two small regions
including residues N142-K144 and R167-N169. Assignments for E36, T52, E59 and R137 are
available for wild-type PRL-1, although no 13C chemical shift information is available for
R137. N27, A111 and the C-terminal regions missing in PRL-1-C170S-C171S were also not
assigned in the oxidized wild type and are likely undergoing conformational exchange. More
importantly, the residues comprising the PTPase active site were fully assigned for PRL-1-
C170S-C171S. This information was missing in wild-type PRL-1 and should prove to be useful
for NMR-based drug screening assays. More than 80% of the aliphatic side chains were
assigned using the CCCONH experiment. The assignments have been deposited in the
BioMagResBank under the accession number 15949 (http://www.bmrb.wisc.edu). Figure 1
shows the 1H-15N HSQC spectrum of PRL-1-C170S-C171S with peaks labeled.
The assignments for PRL-1-C170S-C171S correlate well with the assignments previously
published for PRL-2 and PRL-3 under reducing conditions, indicating that the C170S-C171S
mutant is in fact a reduced species. Comparison of PRL-1-C170S-C171S assignments to the
non-reduced wild type reveals a difference in conformation between the reduced and oxidized
species, which is illustrated in Figure 2a. Overall, more than 90% of the backbone amide
resonances shift upon reduction, which is illustrated graphically in Figure 3. Exceptions include
G123 and Y126, located at the opposite end of the central helix from the active site, and several
peaks in the middle of the spectra. The backbone NH resonance of C49, which forms a disulfide
bond with the active site residue C104, shifts significantly upfield by more than 9 ppm in
nitrogen (Figure 3b) and 1 ppm in proton (Figure 3a) with the C170S-C171S mutation, which
is also observed in wild type upon chemical reduction. The NH chemical shift of the C49
residue changes to a much greater extent than C104; nonetheless, this shift is significant with
the peak moving upfield just under 1 ppm in nitrogen (Figure 3b) and 0.1 ppm in proton (Figure
3a). Cβ chemical shifts can indicate the redox state of cysteine residues (Sharma and
Rajarathnam 2000), and accordingly, the Cβ chemical shifts of the C104 and C49 residues
differ between the reduced and oxidized states. The Cβ shifts for C49 and C104 in non-reduced
wild type are 35.21 and 36.36 ppm, respectively, while the Cβ shift for C49 is 34.01 and the
Cβ peak for C104 is 29.82 ppm. The upfield shift indicates the cysteine residues are in the
reduced state in PRL-1-C170S-C171S. The wild-type PRL-1 forms a disulfide bond and is
reduced by dithiothreitol, which is in agreement with the Trypsin digest/MS data (not shown).
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Lastly, the 1H-15N HSQC spectra of PRL-1-C170S-C171S overlays exceptionally well with
chemically reduced wild-type PRL-1 (Figure 2b) and does not change with the addition of thiol
modulating agents (data not shown). This parallels the finding that PRL-1-C170S-C171S
activity also does not change with the addition of DTT (data not shown). Together, the data
indicate that PRL-1-C170S-C171S represents the active form of this phosphatase, which can
be used to facilitate NMR-based drug screening to identify molecules that inhibit its activity.
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HSQC of 2 mM PRL-1-C170S-C171S in 50 mM sodium phosphate, pH 6.5 and 37°C. The
spectrum was collected on a Bruker 800 MHz Avance spectrometer equipped with a cryogenic
triple resonance probe.
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PRL-1 Overlays. Panel a illustrates the differences between PRL-1-C170S-C171S (black) and
wild-type PRL-1 (red). The C49 and C104 residues in PRL-1-C170S-C171S are highlighted
by a black box. A red box highlights the C104 and C49 residues in PRL-1-WT. Panel b displays
an overlay of PRL-1-C170S-C171S (black) with chemically reduced PRL-1-WT (red).
Reduction of the wild type was accomplished by the addition of 10 mM DTT. The majority of
peaks in the wild type shift upon reduction to positions very similar to PRL-1-C170S-C171S.
The small number of unique peaks in the spectra is likely a result of dynamic differences that
arise from chemical modulation of the disulfide bond.
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Chemical shift differences between PRL-1-WT and PRL-1-C170S-C171S. Panel a shows
differences in proton chemical shifts and panel b illustrates changes in nitrogen chemical shifts.
Δδ was calculated by subtracting δ (ppm) for PRL-1-C170S-C171S from δ (ppm) for PRL-1-
WT. Residues denoted with *, º and † were either not assigned for both PRL-1 variants, assigned
for wild type but not the mutant or assigned for the mutant and not wild type, respectively.
Consequently, a Δδ value for these residues was not calculated and appears to be zero in the
figure.
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